argenx SE
ARGX-121
IgA nephropathy (IgAN)
Countdown
86days
Phase 2 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 2 trial results for ARGX-121 in IgA nephropathy (IgAN) are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 11h ago
“Phase 2 study of ARGX-121 in IgA nephropathy (IgAN) expected to start in 2026”